Ohr Pharmaceutical, Inc. Announces Pricing of $7.75 Million Public Offering of Common Stock and Warrants
December 08, 2016 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Dec. 08, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it has priced a registered public offering...
Ohr Pharmaceutical Announces Proposed Public Offering of Common Stock and Warrants
December 07, 2016 16:07 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Dec. 07, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it intends to offer and sell, subject to...
Ohr Pharmaceutical to Present at 2016 Ophthalmology Innovation Summit on October 13
October 11, 2016 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Oct. 11, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that the company has been selected to present...
Ohr Pharmaceutical Reports Third Quarter 2016 Financial and Business Results
August 09, 2016 16:01 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its third quarter ended June 30,...
Ohr Pharmaceutical to Announce Third Quarter 2016 Financial Results on August 9
August 02, 2016 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, Aug. 02, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for the...
Ohr Pharmaceutical Reports Second Quarter 2016 Financial and Business Results
May 10, 2016 16:01 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, May 10, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today reported results for its second quarter ended March 31,...
Ohr Pharmaceutical Announces Appointment of David Brown, MD as Chair of Phase 3 Clinical Program Steering Committee
May 02, 2016 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, May 02, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that David M. Brown, MD, Clinical Professor of...
Ohr Pharmaceutical Announces Presentations at the 2016 Association for Research in Vision and Ophthalmology (ARVO) Conference in Seattle, WA
April 27, 2016 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, April 27, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced the details of two poster presentations at...
Ohr Pharmaceutical to Announce Second Quarter 2016 Financial Results on May 10
April 26, 2016 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, April 26, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (Nasdaq:OHRP), an ophthalmology research and development company, today announced that it will report financial results for...
Ohr Pharmaceutical, Inc. Announces Enrollment of First Patient in Phase III Wet AMD Clinical Program
April 18, 2016 08:00 ET
|
Ohr Pharmaceutical, Inc.
NEW YORK, April 18, 2016 (GLOBE NEWSWIRE) -- Ohr Pharmaceutical, Inc. (NASDAQ:OHRP), a clinical-stage biotechnology company developing novel therapies for ophthalmic diseases, today announced that...